These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 9201199)

  • 1. Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
    Clarke SJ; Boyer MJ
    Med J Aust; 1997 Jun; 166(S1):S14-6. PubMed ID: 9201199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
    Clegg A; Scott DA; Hewitson P; Sidhu M; Waugh N
    Thorax; 2002 Jan; 57(1):20-8. PubMed ID: 11809985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
    Waters JS; O'Brien ME
    Br J Cancer; 2002 Aug; 87(5):481-90. PubMed ID: 12189541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Second-line and beyond: Docetaxel in the treatment of non-small-cell lung cancer].
    Rinaldi M
    Tumori; 2001; 87(6):A6-9. PubMed ID: 11995708
    [No Abstract]   [Full Text] [Related]  

  • 7. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
    Ferrigno D; Buccheri G
    Lung Cancer; 2000 Aug; 29(2):91-104. PubMed ID: 10963840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Docetaxel].
    Takigawa N
    Nihon Rinsho; 2002 May; 60 Suppl 5():349-52. PubMed ID: 12101686
    [No Abstract]   [Full Text] [Related]  

  • 10. [New cytostatics in the therapy of non-small cell bronchial carcinoma].
    Serke M; Schönfeld N; Loddenkemper R
    Pneumologie; 1998 Jun; 52(6):333-7. PubMed ID: 9715648
    [No Abstract]   [Full Text] [Related]  

  • 11. Promising new agents in the treatment of non-small cell lung cancer.
    Edelman MJ; Gandara DR
    Cancer Chemother Pharmacol; 1996; 37(5):385-93. PubMed ID: 8599859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
    Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
    Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
    Boyer MJ
    Chest; 1998 Jan; 113(1 Suppl):24S-27S. PubMed ID: 9438686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drugs for treating small cell lung cancer.
    Ettinger DS
    Lung Cancer; 1995 Jun; 12 Suppl 3():S53-61. PubMed ID: 7551957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New chemotherapeutic agents for non-small cell lung cancer.
    Miller VA; Rigas JR; Grant SC; Pisters KM; Kris MG
    Chest; 1995 Jun; 107(6 Suppl):306S-311S. PubMed ID: 7781411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
    Green MR
    Semin Oncol; 2002 Jun; 29(3 Suppl 12):17-21. PubMed ID: 12170447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drugs in non-small cell lung cancer. An overview.
    Giaccone G
    Lung Cancer; 1995 Apr; 12 Suppl 1():S155-62. PubMed ID: 7551924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Maintenance chemotherapy in advanced NSCLC].
    Krazkowski M
    Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S16-8. PubMed ID: 16719150
    [No Abstract]   [Full Text] [Related]  

  • 19. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy.
    Khuri FR
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel: new indication. First-line treatment of non small-cell lung cancer: no advance.
    Prescrire Int; 2005 Feb; 14(75):16-8. PubMed ID: 15751170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.